Barclays
RCUS icon

Barclays’s Arcus Biosciences RCUS Stock Holding History

Barclays’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-5,000
Closed -$108K – 5574
2026
Q1 		$108K Hold
5,000
– – ﹤0.01% 3988
2025
Q4 		$119K Buy
+5,000
New +$102K ﹤0.01% 4529
2024
Q2 		– Sell
-27,000
Closed -$510K – 5224
2024
Q1 		$510K Buy
+27,000
New +$467K ﹤0.01% 3580

Other funds holding RCUS

GS
Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Barclays's RCUS Position: Q2 2026 in Review

Barclays reduced its Arcus Biosciences (RCUS) stake by 74% in Q2 2026, selling an estimated $1.38M and leaving 19,318 shares worth $596K. The position accounts for ﹤0.01% of the portfolio, ranked #3117.

Barclays first reported a position in RCUS in Q2 2018 and has held it in 33 quarters since. The position peaked at $26.5M in Q4 2025. 232 funds tracked by Wall St. Rank hold RCUS as of Q2 2026.

  • Barclays held 19,318 shares of Arcus Biosciences worth $596K as of Q2 2026.
  • Barclays sold 55,659 Arcus Biosciences shares in Q2 2026, an estimated $1.38M.
  • Arcus Biosciences made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #3117 holding.
  • Barclays first reported a position in Arcus Biosciences in Q2 2018 and has held it in 33 quarters since.
  • Barclays's Arcus Biosciences position peaked at $26.5M in Q4 2025.
  • 232 funds tracked by Wall St. Rank held Arcus Biosciences as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.